Dexcom, Fitbit bring CGM data to smartwatch

dexcom g5 system including cell phone and app
Starting in 2018, users may see their Dexcom CGM data alongside activity data on their Fitbit Ionic smartwatch. (Dexcom)

Dexcom and Fitbit are teaming up to develop and market products to help people manage their diabetes, starting with integrating Dexcom's continuous glucose monitoring data into one of Fitbit’s smartwatches.

Specifically, patients who view their Dexcom CGM data on a smartphone may now see it on Fitbit’s latest smartwatch. The Fitbit Ionic offers a blood oxygen saturation sensor and improved heart rate tracking in addition to its core features, such as sleep tracking.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The collaboration between Dexcom and Fitbit is an important step in providing useful information to people with diabetes that is both convenient and discreet,” said Dexcom CEO Kevin Sayer, in a statement. “We believe that providing Dexcom CGM data on Fitbit Ionic, and making that experience available to users of both Android and iOS devices, will have a positive impact on the way people manage their diabetes.”

RELATED: Verily reveals research-focused wearable health tracker

The companies plan to roll out the integration in 2018 and will continue to work on other offerings to help people better manage their diabetes.

Dexcom markets the only FDA-approved therapeutic CGM system, meaning that data from the device may be used to make treatment decisions. Other CGMs are approved as adjunctive devices, and so must be used alongside data from other devices.

Dexcom has been ramping up its partnerships lately--most recently, it signed a deal with Ascensia to provide the latter’s blood glucose meter as part of its CGM system. And in June, Glooko and Dexcom expanded their partnership to allow Dexcom CGM data to sync with Glooko’s diabetes management platform via the cloud.

Suggested Articles

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.

The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.